Preferentially Expressed Antigen In Melanoma (PRAME)

[Edit]

MAPE; OIP4; CT130; Cancer/Testis Antigen 130; Opa-interacting protein 4; Melanoma antigen preferentially expressed in tumors

Preferentially Expressed Antigen In Melanoma (PRAME)
PRAME is predominantly expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. This expression pattern is similar to that of other CT antigens, such as MAGE, BAGE and GAGE. However, unlike these other CT antigens, this gene is also expressed in acute leukemias. The deduced 509-amino acid PRAME protein contains no signal sequence. Northern blot analysis detected 2.2- and 3.0-kb PRAME transcripts in tumor cell lines but not in normal tissue except testis. RT-PCR analysis detected very low expression of PRAME in ovary and adrenals. Functional analysis showed that PRAME-specific CTLs can lyse MEL.B but not MEL.A cells due to inhibition mediated by the interaction of a p58.2 molecule (KIR2DL2) on the CTLs with HLA-Cw7 on the melanoma target cell.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPH323Hu01 Recombinant Preferentially Expressed Antigen In Melanoma (PRAME) Positive Control; Immunogen; SDS-PAGE; WB.
RPH323Hu02 Recombinant Preferentially Expressed Antigen In Melanoma (PRAME) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAH323Hu01 Polyclonal Antibody to Preferentially Expressed Antigen In Melanoma (PRAME) WB; IHC
PAH323Hu02 Polyclonal Antibody to Preferentially Expressed Antigen In Melanoma (PRAME) WB; IHC; ICC; IP.
Assay Kits SEH323Hu ELISA Kit for Preferentially Expressed Antigen In Melanoma (PRAME) Enzyme-linked immunosorbent assay for Antigen Detection.
  1. "Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor."Immunity 6:199-208(1997) [PubMed] [Europe PMC] [Abstract]
  2. "A genome annotation-driven approach to cloning the human ORFeome."Genome Biol. 5:R84.1-R84.11(2004) [PubMed] [Europe PMC] [Abstract]
  3. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  4. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  5. "Using the yeast two-hybrid system to identify human epithelial cell proteins that bind gonococcal Opa proteins: intracellular gonococci bind pyruvate kinase via their Opa proteins and require host pyruvate for growth."Mol. Microbiol. 27:171-186(1998) [PubMed] [Europe PMC] [Abstract]
  6. "The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling."Cell 122:835-847(2005) [PubMed] [Europe PMC] [Abstract]
  7. "PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma."Leuk. Res. 30:1333-1339(2006) [PubMed] [Europe PMC] [Abstract]
  8. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]